Thursday, January 15, 2026

In Detail Full day, Thursday, January 15, 2026, Timezone: America/Chicago

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

AI Summary: A compounding pharmacy has taken legal aim at industry giants Eli Lilly and Novo Nordisk, alleging an anti‑competitive scheme designed to restrict access to their blockbuster GLP‑1 therapies. The lawsuit puts the pharmaceutical titans on the defensive as antitrust concerns mix with therapeutic access debates.

FDA moves to remove suicide warnings from GLP-1 weight loss drugs

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

AI Summary: In a surprising twist, the FDA has decided that the long‐rumored risk of suicidal ideation on popular GLP‑1 weight‐loss drugs may have been overblown. Regulators have now asked drugmakers – including Lilly and Novo Nordisk – to scrub these warnings from product labels, a move that is sure to spark both relief and raised eyebrows among critics.

H.H.S. Reverses Decision to Cut $2 Billion for Mental Health and Addiction Services

Jan Hoffman / nytimes - A day after funding termination notices went out to more than 2,000 programs nationwide, the administration reversed itself and reinstated the money.

AI Summary: After sending termination notices that slashed billions in funding for thousands of substance abuse and mental health programs, the Trump administration abruptly backtracked. Critics blasted the move as a chaotic flip-flop that left vital services in limbo and fueled political outrage.